Outcomes of Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer in One Institution

°áÇÙ¹×È£Èí±âÁúȯ 2014³â 77±Ç 1È£ p.13 ~ p.17

À̼®Á¤(Lee Seok-Jeong) - Ewha Womans University School of Medicine Department of Internal Medicine
°­ÇöÁÖ(Kang Hyun-Ju) - Ewha Womans University School of Medicine Department of Internal Medicine
±è¼­¿ì(Kim Seo-Woo) - Ewha Womans University School of Medicine Department of Internal Medicine
(Ryu You-Ju) - Ewha Womans University School of Medicine Department of Internal Medicine
ÀÌÁøÈ­(Lee Jin-Hwa) - Ewha Womans University School of Medicine Department of Internal Medicine
±èÀ¯°æ(Kim Yoo-Kyung) - Ewha Womans University School of Medicine Department of Radiology
ÀåÁßÇö(Chang Jung-Hyun) - Ewha Womans University School of Medicine Department of Internal Medicine

Abstract

Background: This study analyzed the negative prognostic factors in patients who received second-line chemotherapy for advanced inoperable non-small cell lung cancer (NSCLC).

Materials and Methods: We retrospectively reviewed the records of 137 patients with inoperable stage III?IV NSCLC who received second-line chemotherapy. The effects of clinical parameters on survival were analyzed and the hazard ratios (HR) for mortality were identified by a Cox regression analysis.

Results: Sex, age older than 65 years, smoking history, cell type, T-stage, best response to first-line chemotherapy and first-line chemotherapy regimen were significant negative predictors in univariate analysis. The multivariate analysis showed that patients older than 65 years (HR, 1.530; 95% confidence interval [CI], 1.020?2.297), advanced T stage (T4 vs. T1; HR, 2.273; 95% CI, 1.010?5.114) and non-responders who showed progression with first-line chemotherapy (HR, 1.530; 95% CI, 1.063?2.203) had higher HR for death.

Conclusion: The age factor, T stage and responsiveness to first-line chemotherapy were important factors in predicting the outcome of patients with advanced NSCLC who received second-line chemotherapy. The results may help to predict outcomes for these patients in the future.

Å°¿öµå

Age Groups, Carcinoma, Non-Small-Cell Lung, Drug Therapy, Survival
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
Age over 65 years, T4 tumor stage, and poor response to first-line chemotherapy were the most influential predictors of survival after second-line chemotherapy in this study.The age factor, T stage and responsiveness to first-line chemotherapy were important factors in predicting the outcome of patients with advanced NSCLC
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå